Table 3. Uveal melanoma: Long-term survival.
Published data and methods.
| Author, Year | Setting N | Follow up years Median (range) | Method | Year since diagnosis / treatment | Comment | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 15 | 20 | 25 | 30 | 35 | ||||||
| 1 | Jensen 1981 | National (Denmark) 302 | 25 (25–25) | 1-MFS | 50 | 58 | 60 | X | X | Iris included |
| 2 | Kujala 2003 | National Finland 289 | 28 | Competing Risks | 45 | 48 | 49 | 50 | 52 | Iris excluded |
| 3 | Shields 2009 | Institutional 8033 | 2.8 (0–36.3) | 1-MFS^ | 32 | 37 | X | X | X | Iris included |
| 4 | Lane 2015 | Institutional 1490 | 12.3 (1–33.5) | 1-MFS | 25 | 26 | 26 | X | X | Iris excluded |
| 5 | Bagger 2018 | National Denmark 1637 | 5.1 (0.01–32.6) | Competing Risks | 34 | 44 | 44 | 44 | X | Iris excluded |
| 6 | Present Study 2020 | National US 10678 | 5.3 (0.02–42.6) | 1-MFS | 31 | 35 | 37 | 38 | 39 | Iris included |
| Competing Risks | 27 | 29 | 30 | 30 | 31 | |||||
| 1-RS | 35 | 40 | 40 | 40 | * | |||||
| EAR | 37 | 41 | 42 | 42 | 43 | |||||
^data shown for medium sized tumors only.
*unstable.